Major Depressive Disorder

Caplyta, now FDA-approved as an adjunctive therapy for major depressive disorder, offers rapid relief and a favorable safety profile for patients. Learn more from Suresh Durgam, MD, the primary investigator.

Neurocrine's NBI-1070770 fails to meet primary endpoint in phase 2 trial for major depressive disorder, prompting further analysis of results.

AtaiBeckley reveals promising phase 2b open-label extension study results for BPL-003, showing sustained antidepressant effects in patients with treatment-resistant depression after redosing.

Johnson & Johnson's Caplyta gains FDA approval as an adjunctive treatment for major depressive disorder, offering hope for improved patient outcomes.

A reproductive psychiatrist discusses the implications of recent FDA announcements on medication use during pregnancy, emphasizing the importance of mental health for mothers and babies.

New data indicates safety of seltorexant and its pharmacokinetics in treating adolescent depression, supporting its potential as an effective adjunct therapy.

Esketamine nasal spray shows significant improvements in treatment-resistant depression, with effective dose management and minimal adverse effects in recent studies.

New research highlights lumateperone's effectiveness as an adjunctive treatment for major depressive disorder, improving depressive symptoms and sexual function.

Late-life depression poses unique challenges, impacting cognitive function and requiring tailored treatment strategies for older adults.

New phase 3 data highlights seltorexant's potential as a safer adjunctive treatment for major depressive disorder with insomnia, despite not meeting primary end points. Andrew J. Cutler, MD, shares his thoughts.

A phase 2 study reveals osavampator significantly reduces depression severity in adults with major depressive disorder, showing promise for treatment-resistant cases.

Apathy significantly affects cognitive impairment patients, yet remains underrecognized. Discover effective assessment and treatment strategies for improved outcomes.

New phase 2a study reveals promising results for BPL-003, with a 2-dose regimen improving outcomes for patients with treatment-resistant depression.

New phase 3 data reveals seltorexant's potential as a safer adjunctive treatment for major depressive disorder with insomnia, despite not meeting its primary end point.

Esketamine nasal spray shows significant improvement in emotional blunting for treatment-resistant depression, offering hope for affected patients.

New study shows lumateperone (Caplyta) significantly improves symptoms in major depressive disorder with anxious distress, offering hope for treatment-resistant patients.

A groundbreaking trial reveals ANK3 as a potential genetic predictor for liafensine's effectiveness in treating resistant depression.

Onfasprodil shows promise as a rapid treatment for resistant depression, offering fewer side effects than ketamine in recent clinical trials.

FDA clears accelerated deep TMS protocol for major depressive disorder, offering faster treatment with similar outcomes and fewer visits.

It is time to redefine treatment resistance, a definition in which we emphasize comprehensive evaluations and personalized approaches for better patient outcomes.

Untreated maternal mental health issues during pregnancy pose significant risks. Informed discussions on medication are crucial for mother and baby's well-being.

Antidepressant treatment for late-life depression enhances cognitive functions like memory and learning, linking symptom relief to cognitive improvement.

NRx Pharmaceuticals secures FDA Fast Track designation for NRX-100, a preservation-free formulation of intravenous ketamine for suicidal ideation in depression.

Stay updated on key psychopharmacology developments, including new treatments for schizophrenia and breakthroughs in depression therapy.

Youth with neurodevelopmental disorders face significant suicide risks.